Parion Sciences   Report issue

For profit Phase 2
Founded: Durham NC United States (1999)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2006
NCT00274313
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ciliary Motility Disorders (Phase 2)

Cystic Fibrosis (Phase 2)

Dry Eye Syndromes (Phase 2)

Dyskinesias (Phase 2)

Eye Diseases (Phase 2)

Fibrosis (Phase 2)

Kartagener Syndrome (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Sjogren's Syndrome (Phase 2)

Syndrome (Phase 2)

Xerostomia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 7